However, the MDM2-p53 interaction is a crucial regulatory mechanism in cancer cells; this particular interaction may also contribute to the biological and molecular changes observed in CD34+ CML cells under PAK6 inhibition. The gene discussed is TP53; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.